Average Co-Inventor Count = 6.99
ph-index = 4
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Deutsches Krebsforschungszentrum (11 from 155 patents)
2. Ruprecht-karls-universitat Heidelberg (4 from 63 patents)
3. Ruprecht-karls-universitaet Heidelberg (4 from 23 patents)
4. Novartis Ag (2 from 3,923 patents)
5. Ruprecht-karls-universität (7 patents)
13 patents:
1. 12156920 - Double-labeled probe for molecular imaging and use thereof
2. 12054458 - F-tagged inhibitors of prostate specific membrane antigen (PSMA) and their use as imaging agents for prostate cancer
3. 11951190 - Use of labeled inhibitors of prostate specific membrane antigen (PSMA), as agents for the treatment of prostate cancer
4. 11931430 - Labeled inhibitors of prostate specific membrane antigen (PSMA) as agents for the treatment of prostate cancer
5. 11638765 - Double-labeled probe for molecular imaging and use thereof
6. 11452786 - Double-labeled probe for molecular imaging and use thereof
7. 11045564 - Labeled inhibitors of prostate specific membrane antigen (PSMA) as agents for the treatment of prostate cancer
8. 11020493 - Double-labeled probe for molecular imaging and use thereof
9. 10815200 - 18F—tagged inhibitors of prostate specific membrane antigen (PSMA) and their use as imaging agents for prostate cancer
10. 10471160 - Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
11. 10406246 - Double-labeled probe for molecular imaging and use thereof
12. 10398791 - Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
13. 10016519 - 18F-tagged inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer